News

The Orphan Drug Designation has been granted for the combination of two active ingredients of AB569: sodium nitrite and ethylenediaminetetraacetic acid. AB569 is to be administered to patients

Mylan offered $75 in cash and 2.3 ordinary shares for each Perrigo share. Perrigo has however called the Mylan proposal inadequate. Following the offer expiry, Mylan executive chairman

The Phase III trial assessed Imbruvica plus bendamustine and rituximab (BR) versus placebo plus BR in relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The results

The nexgen-PTS expands the company’s microbial solutions offering within its microbiology portfolio, which features microbial detection, bioburden testing and microbial identification. The Endosafe nexgen-PTS features touch screen display,

Xadago, which is being developed by Zambon and its partner Newron Pharmaceuticals, was approved as add-on therapy to levodopa (L-dopa) alone or in combination with other PD therapies

Tagrisso is indicated to treat patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). In two clinical trials of 411 subjects, 57%

The terms of the transaction were not disclosed. Oasis designs, develops, manufactures and sells pre-analytic tools for the collection, preservation, and transportation of saliva/oral fluids. Oasis’ focus is

This collaboration builds on positive proof of concept data published in the journal "Blood" demonstrating that ex vivo treatment of Tregs with TZ101 prior to administration is an

The investment syndicate includes existing investors, including BlueWater Angels, and new investors RBV Capital, ExSight Capital, and Santen Pharmaceutical. Earlier in 2015, RetroSense Therapeutics closed a $7m Series